Genmab A/S (NASDAQ:GMAB) Downgraded by Wall Street Zen to Hold

Genmab A/S (NASDAQ:GMAB) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Other equities research analysts have also issued research reports about the company. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Tuesday, September 23rd. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Truist Financial reissued a “buy” rating and issued a $48.00 price target (down from $49.00) on shares of Genmab A/S in a report on Thursday. Finally, HC Wainwright restated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.50.

Genmab A/S Trading Down 0.6%

NASDAQ GMAB traded down $0.18 on Friday, reaching $28.66. 2,026,734 shares of the stock were exchanged, compared to its average volume of 2,648,188. Genmab A/S has a one year low of $17.24 and a one year high of $33.65. The firm has a market capitalization of $18.40 billion, a PE ratio of 12.20, a PEG ratio of 1.57 and a beta of 0.96. The company’s 50-day simple moving average is $29.61 and its two-hundred day simple moving average is $24.43.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a net margin of 41.36% and a return on equity of 24.48%. Sell-side analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors have recently bought and sold shares of GMAB. Cromwell Holdings LLC increased its holdings in shares of Genmab A/S by 136.3% in the 3rd quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock worth $47,000 after buying an additional 883 shares during the last quarter. Headlands Technologies LLC lifted its holdings in shares of Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after acquiring an additional 1,464 shares during the last quarter. Osaic Holdings Inc. increased its stake in Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after acquiring an additional 440 shares during the last quarter. CWM LLC raised its position in Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after purchasing an additional 603 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after purchasing an additional 1,070 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.